This Dividend Stock Has Plunged Ahead of Trump’s Inauguration. Here Are 3 Reasons Investors Should Still Buy It.
The stock market has experienced significant shifts following Donald Trump’s election, as investors reposition their portfolios in anticipation of the new administration's policies. One sector that has been particularly affected is pharmaceuticals and healthcare, which was already facing downward pressure. This decline continued after President-elect Trump nominated Robert F. Kennedy, Jr. to lead the Department of Health and Human Services (HHS). Kennedy, a known vaccine skeptic, triggered a market reaction that led to a selloff in vaccine manufacturers, including pharmaceutical giant Pfizer (NYSE: PFE). After falling 10% in 2022 and 41% in 2023, Pfizer ended 2024 with a 2% decline, trading around $26 per share. Given its multi-year low, many investors are questioning whether now is the right time to buy or sell Pfizer stock as Trump’s inauguration approaches. In this article, we’ll examine the reasons behind Pfizer’s price drop and why it may still be a compelling investment. Why ...